Impact of the Adherence to Antiemetic Guidelines in Cancer Patients Undergoing Repeated Cycles of Either MEC or HEC Regimens in Eastern Europe (NERO - NAUSEA/EMESIS REGISTRY IN ONCOLOGY)

Study identification

• EU PAS number:
  EUPAS25577
• Study ID:
  25578
• Official title and acronym:
  Impact of the Adherence to Antiemetic Guidelines in Cancer Patients Undergoing Repeated Cycles of Either MEC or HEC Regimens in Eastern Europe (NERO - NAUSEA/EMESIS REGISTRY IN ONCOLOGY)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Bulgaria

  Czechia

  Poland

  Romania

  Slovakia
• Study description:
  Multicentric non-interventional prospective study assessing antiemetic guidelines consistency in CINV prophylaxis and the impact of CINV on the quality of life on cancer patients receiving MEC or HEC.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Institute of Biostatistics and Analyses (IBA)

Czechia

Study timelines

Date when funding contract was signed

Planned:14/12/2015

Actual:14/12/2015

Study start date

Actual:28/09/2016

Date of final study report

Planned:30/09/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Angelini Pharma Oesterreich, GmbH

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable